Cambridge, Massachusetts-based Spero Therapeutics, a biopharmaceutical company targeting drug resistant bacterial infections, raised $30 million in Series B preferred financing, matching the $30 million Series A round Spero raised in June. Existing Series A investors Atlas Venture, SR One, MRL Ventures, Lundbeckfond Ventures, The Kraft Group and Partners Innovation Fund all returned to participated.